Literature DB >> 17499716

Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes.

Céline Lévêque1, Véronique Marsaud, Jack-Michel Renoir, Brigitte Sola.   

Abstract

Cyclin D1 is an important regulator of the early phase of the cell cycle and the transcriptional machinery. It is often deregulated in human tumors of various origins and is considered to be an oncogene. The CCND1 gene encoding cyclin D1 generates two mRNAs by alternative splicing, leading to the production of two alternative proteins: a long form a (36 kDa) and a short form b (30-31 kDa) from which the C-terminal moiety required for protein stability and sub-cellular localization has been deleted. Both forms of RNA and protein have been detected in B-cell hemopathies, but their respective roles are unclear. We investigated the function of cyclin D1b in cell cycle regulation, by generating B-cell lines displaying conditional expression of isoform b. Comparisons of these cell lines (BD1b series) with previously obtained cell lines expressing cyclin D1a demonstrated that cyclin D1b had no cell cycle regulatory properties.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499716     DOI: 10.1016/j.yexcr.2007.04.018

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Authors:  Maria Paola Paronetto; Manuela Cappellari; Roberta Busà; Simona Pedrotti; Roberta Vitali; Clay Comstock; Terry Hyslop; Karen E Knudsen; Claudio Sette
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 2.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

3.  Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Di Jiang; Yan Jiang; Shulan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer.

Authors:  Meili Hao; Xiangmei Chen; Ting Zhang; Tao Shen; Qing Xie; Xiujuan Xing; Hongxi Gu; Fengmin Lu
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

5.  Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Authors:  Véronique Marsaud; Guergana Tchakarska; Geoffroy Andrieux; Jian-Miao Liu; Doulaye Dembele; Bernard Jost; Joanna Wdzieczak-Bakala; Jack-Michel Renoir; Brigitte Sola
Journal:  Mol Cancer       Date:  2010-05-10       Impact factor: 27.401

6.  Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Authors:  Vanita K Gupta; Andrew Feber; Liqiang Xi; Arjun Pennathur; Maoxin Wu; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Authors:  Clay E S Comstock; Michael A Augello; Ruth Pe Benito; Jason Karch; Thai H Tran; Fransiscus E Utama; Elizabeth A Tindall; Ying Wang; Craig J Burd; Eric M Groh; Hoa N Hoang; Graham G Giles; Gianluca Severi; Vanessa M Hayes; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Christopher A Haiman; Raffaele Baffa; Leonard G Gomella; Erik S Knudsen; Hallgeir Rui; Susan M Henshall; Robert L Sutherland; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

Review 8.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

9.  Investigation of cyclin D1 rs9344 G>A polymorphism in colorectal cancer: a meta-analysis involving 13,642 subjects.

Authors:  Hao Qiu; Chengguo Cheng; Yafeng Wang; Mingqiang Kang; Weifeng Tang; Shuchen Chen; Haiyong Gu; Chao Liu; Yu Chen
Journal:  Onco Targets Ther       Date:  2016-10-27       Impact factor: 4.147

10.  The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

Authors:  Niels Weinhold; David C Johnson; Daniel Chubb; Bowang Chen; Asta Försti; Fay J Hosking; Peter Broderick; Yussanne P Ma; Sara E Dobbins; Dirk Hose; Brian A Walker; Faith E Davies; Martin F Kaiser; Ni L Li; Walter A Gregory; Graham H Jackson; Mathias Witzens-Harig; Kai Neben; Per Hoffmann; Markus M Nöthen; Thomas W Mühleisen; Lewin Eisele; Fiona M Ross; Anna Jauch; Hartmut Goldschmidt; Richard S Houlston; Gareth J Morgan; Kari Hemminki
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.